Cargando…

Kidney Transplantation and Monoclonal Gammopathy of Undetermined Significance

Plasma cell disorders are one of the most common hematologic malignancies. Monoclonal gammopathy of undetermined significance (MGUS) is defined by a serum monoclonal protein <3 g/dL, bone marrow plasma cell infiltration <10%, and most importantly absence of end-organ damage. The prevalence of...

Descripción completa

Detalles Bibliográficos
Autores principales: Aslam, Nabeel, Trautman, Christopher L., Sher, Taimur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274733/
https://www.ncbi.nlm.nih.gov/pubmed/34263021
http://dx.doi.org/10.1097/TXD.0000000000001176
_version_ 1783721597733961728
author Aslam, Nabeel
Trautman, Christopher L.
Sher, Taimur
author_facet Aslam, Nabeel
Trautman, Christopher L.
Sher, Taimur
author_sort Aslam, Nabeel
collection PubMed
description Plasma cell disorders are one of the most common hematologic malignancies. Monoclonal gammopathy of undetermined significance (MGUS) is defined by a serum monoclonal protein <3 g/dL, bone marrow plasma cell infiltration <10%, and most importantly absence of end-organ damage. The prevalence of MGUS in general population is estimated to be 1%–4% and its frequency increases with age with 3% among people above 50 y of age. The risk of progression to clinically significant plasma cell dyscrasia is estimated to be 1% per year. With aging population and increasing use of transplantation for the management of kidney disease in older adults, MGUS is being identified during the evaluation for kidney transplant candidacy or during the postkidney transplant follow-up. MGUS in patients with end-stage renal disease (ESRD) undergoing evaluation for kidney transplant can pose a complex management dilemma. In this article, we review the current state of knowledge about the prevalence of MGUS in ESRD population and the impact of kidney transplantation on the progression of MGUS to clinically significant plasma cell disorder. We make recommendations for the screening of ESRD patients undergoing kidney transplant evaluation and the management of MGUS after renal transplant.
format Online
Article
Text
id pubmed-8274733
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-82747332021-07-13 Kidney Transplantation and Monoclonal Gammopathy of Undetermined Significance Aslam, Nabeel Trautman, Christopher L. Sher, Taimur Transplant Direct Review Plasma cell disorders are one of the most common hematologic malignancies. Monoclonal gammopathy of undetermined significance (MGUS) is defined by a serum monoclonal protein <3 g/dL, bone marrow plasma cell infiltration <10%, and most importantly absence of end-organ damage. The prevalence of MGUS in general population is estimated to be 1%–4% and its frequency increases with age with 3% among people above 50 y of age. The risk of progression to clinically significant plasma cell dyscrasia is estimated to be 1% per year. With aging population and increasing use of transplantation for the management of kidney disease in older adults, MGUS is being identified during the evaluation for kidney transplant candidacy or during the postkidney transplant follow-up. MGUS in patients with end-stage renal disease (ESRD) undergoing evaluation for kidney transplant can pose a complex management dilemma. In this article, we review the current state of knowledge about the prevalence of MGUS in ESRD population and the impact of kidney transplantation on the progression of MGUS to clinically significant plasma cell disorder. We make recommendations for the screening of ESRD patients undergoing kidney transplant evaluation and the management of MGUS after renal transplant. Lippincott Williams & Wilkins 2021-07-09 /pmc/articles/PMC8274733/ /pubmed/34263021 http://dx.doi.org/10.1097/TXD.0000000000001176 Text en Copyright © 2021 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Review
Aslam, Nabeel
Trautman, Christopher L.
Sher, Taimur
Kidney Transplantation and Monoclonal Gammopathy of Undetermined Significance
title Kidney Transplantation and Monoclonal Gammopathy of Undetermined Significance
title_full Kidney Transplantation and Monoclonal Gammopathy of Undetermined Significance
title_fullStr Kidney Transplantation and Monoclonal Gammopathy of Undetermined Significance
title_full_unstemmed Kidney Transplantation and Monoclonal Gammopathy of Undetermined Significance
title_short Kidney Transplantation and Monoclonal Gammopathy of Undetermined Significance
title_sort kidney transplantation and monoclonal gammopathy of undetermined significance
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8274733/
https://www.ncbi.nlm.nih.gov/pubmed/34263021
http://dx.doi.org/10.1097/TXD.0000000000001176
work_keys_str_mv AT aslamnabeel kidneytransplantationandmonoclonalgammopathyofundeterminedsignificance
AT trautmanchristopherl kidneytransplantationandmonoclonalgammopathyofundeterminedsignificance
AT shertaimur kidneytransplantationandmonoclonalgammopathyofundeterminedsignificance